Tag: orphan drug

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of...

argenx reports first quarter 2018 financial results and provides business update

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment...

Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111

Auris Medical (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, announced today...

8 Glioblastoma Treatment Stocks

With an average survival rate of 16 months, glioblastoma is the most common and deadly type of brain cancer, accounting...

Eloxx Pharmaceuticals Announces FDA Grant of Orphan-Drug Designation for Investigational Drug ELX-02 for Treatment of Cystinosis

Eloxx Pharmaceuticals (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis...

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.

Kalytera Issues CEO Letter to Shareholders

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today issued the following letter to shareholders from the Company’s President...